

# 澳大利亚生物技术协会 澳大利亚医疗技术公司名录



## 公司介绍

公司名称: Clinical Genomics Technologies Pty Ltd

主要联系人姓名: Warren Bingham

主要联系人职务: 亚太地区副总裁

公司网址: [www.clinicalgenomics.com](http://www.clinicalgenomics.com)

公司地址: 15-16/2 Eden Park Drive, North Ryde, NSW 2113

公司未上市

## 公司简介

Clinical Genomics公司利用突破性科学技术, 开发新兴、具开创性、更便捷的方式以预防疾病、提高生活质量。Clinical Genomics成立于2006年并致力于开发新一代用于大肠癌诊断的产品。Clinical Genomics在美国与澳大利亚都有获得监管许可的生产工厂、在澳大利亚悉尼和美国新泽西州爱迪生市设有办公室和实验室, 且是经FDA (美国食品药品监督管理局) 注册、TGA (澳大利亚联邦药管局) 许可的制造商及NATA (澳大利亚国家测试局协会) 认证的实验室。

## 关键技术或领先技术

Clinical Genomics公司拥有对InSure粪便免疫化学测试(FIT)产品‘检测刷 (Brush test)’生产线的专利保护。该产品以ColoVantage Home名称在澳大利亚上市销售。本产品可与新型的血浆检验产品 (ColoVantage Plasma) 配套使用, 对大肠癌进行筛检。此检验组合旨在方便患者使用并成为首选的筛查方案。

ColoVantage Home/Insure粪便免疫化学测试(FIT)首次于2000年面世。如今, 全球有数百万人使用ColoVantage Home粪便免疫化学测试做筛查。临床研究已证实, 即使样本中仅有少量或微乎其微的血液, ColoVantage Home检测仍有高度精准的结果。

Clinical Genomics公司运用已在申请专利的结直肠癌肿瘤生物标志物——甲基DNA进一步发展出一款具高度敏锐性的血检产品, 专门筛检最早期的结直肠癌及尚未有侵袭性的肿瘤。该产品以ColoVantage Plasma名称在澳大利亚上市销售, ColoVantage Plasma与ColoVantage Home皆使用最新技术来检测隐性出血, 以找出可能存在的大肠方面疾病。

## 类别

诊断类：肿瘤诊断

关键技术或领先技术的发展阶段

产品已经上市

合作机会

-

---

## Directory of Australian medtech companies



### **COMPANY DETAILS**

**Company name:** Clinical Genomics Technologies Pty Ltd

**Key contact name:** Warren Bingham

**Job title of key contact:** Vice President, Asia Pacific

**Company website address:** [www.clinicalgenomics.com](http://www.clinicalgenomics.com)

**Company address:** 15-16/2 Eden Park Drive North Ryde NSW 2113

**The company is Unlisted.**

### **ABOUT THE COMPANY**

Clinical Genomics harness breakthrough science to create new, innovative and more accessible ways to prevent disease and enhance lives. Founded in 2006, Clinical Genomics develops next generation products for colorectal cancer diagnosis. Clinical Genomics operates from a regulatory-licensed manufacturing facility in the US and Australia with offices and laboratories in both Sydney, Australia and Edison, New Jersey in the US, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.

### **KEY OR LEAD TECHNOLOGY**

Clinical Genomics owns the patented InSure faecal immunochemical test (FIT) 'Brush test' product line. In Australia this product is now marketed as ColoVantage Home. This product, combined with the new blood plasma test (ColoVantage Plasma), delivers a portfolio of colorectal cancer screening products aimed at user-friendly, patient-preferred screening solutions.

ColoVantage Home/InSure FIT was first released in 2000, ColoVantage Home is a faecal immunochemical test (FIT) that has now been used to screen millions of people around the world. Clinical studies have proven that ColoVantage Home is highly accurate for detecting even tiny or invisible amounts of blood in a sample.

We then applied our patent-pending methyl-DNA biomarkers for colorectal neoplasia to develop a sensitive and specific blood test for the earliest stages of colorectal cancer and pre-invasive neoplasia. The product is marketed in Australia as ColoVantage Plasma alongside the company's ColoVantage Home that uses the latest technology to detect hidden bleeding which may indicate colorectal disease.

**Category**

**Diagnostics:** Diagnostics oncology

**Point of development of key or lead technology**

Product on the market

**OPPORTUNITIES SOUGHT**

-